Improved quality of life and vitality
Cho, Y., Park, Y., Sim, B., Kim, J., Lee, H., Cho, S.-N., Kang, Y., & Lee, S.-G
Common side effects during the adjustment period (typically the first 24 weeks): Mild nausea usually less intense than when first starting a GLP-1 medication Changes in appetite (some patients notice less appetite suppression early on at the starting 0.25 mg dose) Mild stomach discomfort, bloating, or constipation Injection site reactions Side effects that are less likely during the switch (compared to first-time GLP-1 use), but still possible: Significant vomiting less common given prior GLP-1 exposure, but possible Hypoglycemia particularly relevant for type 2 diabetes patients on insulin or sulfonylureas
Certain mechanisms are required to bypass this end-replication problem, which leads to a milestone in telomere research: the identification of telomerase in 1985 by Greider and Blackburn
In sectors like pharmaceuticals